IMVAMUNE®
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Vaccination
Conditions
Vaccination
Trial Timeline
Apr 22, 2010 → Nov 14, 2014
NCT ID
NCT03472014About IMVAMUNE®
IMVAMUNE® is a approved stage product being developed by Bavarian Nordic for Vaccination. The current trial status is completed. This product is registered under clinical trial identifier NCT03472014. Target conditions include Vaccination.
What happened to similar drugs?
0 of 2 similar drugs in Vaccination were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02038881 | Phase 2 | Completed |
| NCT01144637 | Phase 3 | Completed |
| NCT03472014 | Approved | Completed |
Competing Products
6 competing products in Vaccination
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV | Zydus Lifesciences | Phase 3 | 47 |
| Rotavirus Vaccine | Merck | Pre-clinical | 22 |
| HPV vaccine | Merck | Pre-clinical | 26 |
| Bretovameran | Pfizer | Pre-clinical | 30 |
| Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine | Sanofi | Phase 3 | 40 |
| VIGIV | Emergent BioSolutions | Pre-clinical | 23 |